Internal Medicine, Hematology & Oncology · Jacksonville, FL
NPI
1902889959
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
7015 A C Skinner Pkwy, Bldg 100
Jacksonville, FL, 32256
Phone (904) 516-3737
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
87,171 services
Medicare patients, 2024
362
Average age 74
Drug cost, 2024
$1.5M
641 prescriptions
Company payments, 2025
$285
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maria J Valente was code J0897 (injection, denosumab, 1 mg), 3,240 times for 30 patients. In total Maria J Valente billed 87,171 services in 104 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 3,240 | 30 | $20.42 | $66K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2,000 | 19 | $0.10 | $204 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,226 | 18 | $0.09 | $111 |
| 36415 Venipuncture Blood Collection | Office | 897 | 187 | $8.65 | $7,759 |
| 85025 Blood Count | Office | 836 | 180 | $7.61 | $6,362 |
| 99214 Office E&M - Established | Office | 532 | 182 | $93.54 | $50K |
| 96372 Injection Administration | Office | 302 | 55 | $10.35 | $3,127 |
| 96367 Intravenous Infusion, Hydration | Office | 294 | 21 | $21.22 | $6,240 |
| 99213 Office E&M - Established | Office | 221 | 134 | $63.25 | $14K |
| 96413 Chemotherapy Administration | Office | 177 | 23 | $94.66 | $17K |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 140 | 20 | $71.96 | $10K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 139 | 12 | $5.28 | $734 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 135 | 98 | $12.72 | $1,717 |
| J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 119 | 13 | $0.93 | $110 |
| 96365 Intravenous Infusion, Hydration | Office | 98 | 27 | $46.86 | $4,592 |
By year: 2022 $1.1M for 63,439 services; 2023 $1.1M for 71,281 services; 2024 $1.2M for 87,171 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 897 | 187 | $8.65 | $7,759 |
| 85025 Blood Count | 836 | 180 | $7.61 | $6,362 |
| 81002 Clinical Chemistry | 48 | 13 | $3.41 | $164 |
Medicare prescription drug claims, 2024
In 2024, the drug Maria J Valente prescribed most often to Medicare patients was Anastrozole, with 84 prescriptions and refills. In total Maria J Valente wrote 641 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 84 | 206 | 23 | $1,442 |
| Eliquis Apixaban | 64 | 86 | 16 | $49K |
| Gabapentin Generic | 30 | 75 | Under 11 | $530 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 26 | 26 | Under 11 | $793 |
| Ondansetron Odt Ondansetron | 23 | 23 | 21 | $225 |
| Tamoxifen Citrate Generic | 22 | 54 | Under 11 | $611 |
| Lorazepam Generic | 18 | 18 | 11 | $23.43 |
| Xarelto Rivaroxaban | 17 | 28 | Under 11 | $15K |
| Ibrance Palbociclib | 16 | 16 | Under 11 | $251K |
| Prednisone Generic | 16 | 16 | Under 11 | $125 |
| Dexamethasone Generic | 15 | 17 | Under 11 | $256 |
| Levofloxacin Generic | 14 | 14 | 12 | $68.49 |
| Tramadol Hcl Generic | 13 | 13 | Under 11 | $33.73 |
| Imatinib Mesylate Generic | 13 | 13 | Under 11 | $977 |
| Lytgobi Futibatinib | 12 | 12 | Under 11 | $251K |
Brand drugs: - claims; generic drugs: 458 claims; opioid claims: 46.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Maria J Valente $285 ($285 in general payments such as food, travel and fees) from 13 companies. The largest payer was Pfizer Inc. with $44.49.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 2 | $44.49 |
| Agios Pharmaceuticals, Inc. AGIO | 1 | $37.77 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32.27 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $27.51 |
| Daiichi Sankyo Inc. 4568.T | 1 | $23.86 |
| TerSera Therapeutics LLC | 1 | $17.31 |
| Genentech USA, Inc. ROG.SW | 1 | $17.24 |
| Iovance Biotherapeutics, Inc. IOVA | 1 | $15.51 |
| Janssen Biotech, Inc. JNJ | 1 | $14.38 |
| Novocure Inc. NVCR | 1 | $14.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.